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Abstract
Background:  Gene function analysis often requires a complex and laborious sequence of
laboratory and computer-based experiments. Choosing an effective experimental design generally
results from hypotheses derived from prior knowledge or experimentation. Knowledge obtained
from meta-analyzing compendia of expression data with annotation libraries can provide significant
clues in understanding gene and network function, resulting in better hypotheses that can be tested
in the laboratory.
Description: Genevestigator is a microarray database and analysis system allowing context-driven
queries. Simple but powerful tools allow biologists with little computational background to retrieve
information about when, where and how genes are expressed. We manually curated and quality-
controlled 3110 mouse Affymetrix arrays from public repositories. Data queries can be run against
an annotation library comprising 160 anatomy categories, 12 developmental stage groups, 80
stimuli, and 182 genetic backgrounds or modifications. The quality of results obtained through
Genevestigator is illustrated by a number of biological scenarios that are substantiated by other
types of experimentation in the literature.
Conclusion:  The Genevestigator-Mouse database effectively provides biologically meaningful
results and can be accessed at https://www.genevestigator.ethz.ch.
Background
The development of functional genomics technologies
has led in recent years to a proliferation of databases for
storage and delivery of microarray data. Since the intro-
duction of the MIAME standard [1] and associated com-
munity- level annotation guidelines [2-4], experimental
descriptions have become more precise, allowing a better
understanding and reproducibility of experiments, as well
as more efficient querying possibilities. Several databases
offer tools to browse, query and download experiments.
However, in most cases, data is provided as is, without
removal of biased data after systematic processing with
quality-control measures. Furthermore, the focus of most
microarray databases has been in storage and retrieval of
experiments, but only few provide analysis tools opti-
mally interacting with the database. In parallel to these
Published: 21 June 2006
BMC Bioinformatics 2006, 7:311 doi:10.1186/1471-2105-7-311
Received: 31 March 2006
Accepted: 21 June 2006
This article is available from: http://www.biomedcentral.com/1471-2105/7/311
© 2006 Laule et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2006, 7:311 http://www.biomedcentral.com/1471-2105/7/311
Page 2 of 8
(page number not for citation purposes)
developments, several web-based tools have recently been
developed specifically for the analysis of individual
microarray experiments, such as RACE [5] or ArrayQuest
[6]. High-throughput technologies allow to streamline
the same type of analysis for large numbers of genes or
proteins. A major challenge for scientists in this respect is
the sparsity of the data sets, i.e. the low number of meas-
urements relative to the immense number of simultane-
ously tested elements. The analysis of such data structures
often cannot make use of many classical statistical proce-
dures and calls for the development of novel statistical
approaches, such as sparse graphical modeling [7] or
computational approaches that allow to compile result
summaries combining data and annotations.
Genevestigator [8] is a high-quality database combined
with tools to create such result summaries. It reveals novel
and diverse information about when, where and how
genes are expressed in order to foment both discovery and
hypothesis generation. In fact, hypothesis-driven biologi-
cal research solicits models to represent biological proc-
esses. Once models are created, they are tested against
experimental results. The design of models and of the
proper experiments allowing to effectively conclude about
their validity is a crucial step in the discovery process. The
availability, diversity, robustness, and correct interpreta-
tion of prior experimental results, such as those from
microarray experiments, are therefore instrumental in for-
mulating new hypotheses and models, as well as in
designing the proper experiments to test them. Genevesti-
gator-Mouse aims at providing easy-to-use but powerful
tools that enable biologists to obtain context-driven infor-
mation about the expression of the mouse transcriptome.
The information obtained helps to validate existing
hypotheses, as well as to formulate new hypotheses or to
design novel experiments.
Construction and content
Data source, processing, and annotation
Data was downloaded via FTP from public repositories
such as Gene Expression Omnibus [9], ArrayExpress [10],
MUSC [11], PEPR [12], ChipperDB [13] or NIH Neuro-
science Microarray Consortium [14]. Raw data (CEL files)
were normalized with the Affy package from Bioconduc-
tor [18] using the MAS5 algorithm. Experiment annota-
tions were retrieved from public repositories, from
original publications, and occasionally directly from the
authors. Anatomy ontologies, of which 160 are currently
represented in the database, are based on definitions pro-
vided by the Edinburgh Mouse Atlas Project and available
at Mouse Genome Informatics [15]. Developmental
stages are partitioned into 27 pre-natal [16] and 5 post-
natal stages. In the latter case, stages were defined based
on a log(4) scale of time units (days) after birth. Genetic
modifications were systematically annotated according to
the underlying mutagenesis methods, e.g. targeted dele-
tion or ENU mutagenesis and including, if possible, infor-
mation about which genes were affected. As for treatments
and stimuli, several major categories currently cover 80
treated samples (+) and their corresponding controls (-).
Data for the mapping of probe sets to gene identifiers were
obtained from the Affymetrix website [17]. Currently,
either probe set or UniGene identifiers can be used for
querying the database.
Quality control
A prerequisite for the type of analysis provided by Gen-
evestigator is data comparability between experiments.
Although methods how to combine data from different
technological platforms and laboratories are still a matter
of debate, the common analysis of data from a single
organism, a single platform such as the Affymetrix system,
and a single array type has so far proven to successfully
reveal biological mechanisms. In fact, as can be verified
from recent publications, results obtained from Geneves-
tigator with Arabidopsis could be substantiated by other
experimental techniques such as RT-PCR, reporter gene
analysis, mutant phenotyping, or other microarray stud-
ies. In order to maximize comparability, quality-control
(QC) measures were applied to raw and normalized data.
The current QC protocol uses several Bioconductor [18]
packages (simpleaffy, AffyQCReport, AffyPLM) and in-
house R code. QC results include signal intensity box-
plots and density-plots, Actin and GAPDH QC statistics,
RLE, NUSE, RNA digestion plots, positive and negative
border element plots, as well a correlation matrix. QC
reports are publicly available. Array data containing flaws
or biases, or of which RNA was strongly degraded, are
flagged and excluded by default from the data analysis
tools. Currently, approximately 3.4% of arrays did not ful-
fil the QC criteria. However, users can decide whether to
use all the available data by inactivating the default "Qual-
ity Control" option.
Application
The software was developed as a PHP/MySQL application
running on a Linux Apache Web server. Javascript and
cookies must be activated for browsers to correctly run the
application. More details about methods and algorithms
used can be found in the documentation section on the
Genevestigator website [19].
Database and analysis tools
The database contains both 12 K and 40 K Affymetrix
arrays (MG-U74Av2 and Mouse430 2.0). As of June 2006,
3110 arrays from 166 experiments were curated, quality-
controlled and annotated according to controlled vocabu-
laries. Two types of queries can be run: gene-centric (how
is gene X expressed in a series of conditions?) or genome-
centric (which genes are expressed in a pre-selection ofBMC Bioinformatics 2006, 7:311 http://www.biomedcentral.com/1471-2105/7/311
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conditions?). The tools described below contain either
one or both types. Data can be viewed either in linear or
log(2)-scale relative to the following categories:
Experiments and arrays (Digital Northern): the digital
Northern visualizes signal intensity values and present/
absent calls of a subset of genes across a selection of exper-
iments.
Anatomy (Gene Atlas): this tool reveals the anatomy-spe-
cific profiles of single query genes, or reversely allows to
identify genes expressed specifically in a selection of
organs/tissues.
Stimulus (Response Viewer): this tool shows the responses
of genes to a compendium of stimuli. Results can be
sorted such as to rapidly identify those factors most affect-
ing the expression of query genes. Reversely, it allows to
find genes expressed specifically in a subset of conditions.
Development (Gene Chronologer): changes in gene expres-
sion throughout the life cycle of the mouse, which is
grouped into 7 embryo and 5 post-natal stage groups, can
be visualized. Reversely, one can search for genes
expressed specifically at given stages of development.
Mutation  (Mutant Surveyor): this tool is similar to the
Response Viewer, plotting the responses of a query gene to
a number of genetic backgrounds or modifications (e.g.
gene knock-out or overexpression).
Multiple genes (Meta-Analyzer): expression profile sum-
maries of a larger number of genes with respect to anat-
omy, development, or stimulus can be queried.
Documentation: the documentation and FAQ sections pro-
vide important technical and practical information about
the tools, such as statistical procedures, probe set specifi-
city, normalization, how to interpret data, and precau-
tions to avoid over-interpretation.
Database: this page provides information about all exper-
iments stored in our database, including data source
repositories, authors, publications, dates, original file
names, Genevestigator file names, annotations, quality-
control results, and links to external information. Since
Genevestigator is basically a data analysis tool and not a
repository, we do not provide data bulk download
options and therefore recommend users to download the
data from the original repositories.
Utility and discussion
A validation and discovery study is presented to illustrate
some of the querying possibilities and to assess the quality
of the output by comparison to prior biological knowl-
edge obtained from the literature. Besides confirming pre-
viously known mechanisms, we present novel findings
and hypotheses about the regulation of given genes in
mouse.
Our database encompasses a wide range of experimentally
annotated gene expression data covering diverse catego-
ries i.e. different tissues, developmental stages, treatments
and genetic modifications. Since the averages computed
for each category are based on data from a variety of exper-
imental setups that are not necessarily systematic through-
out all categories, care must be taken not to over-interpret
results. Our general hypothesis is that an increase in the
number of experiments and replicates per defined cate-
gory generally attenuates experiment specific effects in
favor of global trends. To verify whether results from Gen-
evestigator show robust and reproducible trends, we
selected from the literature a number of genes with expres-
sion profiles specific to organs or to developmental stages,
or genes responsive to certain stimuli or to genetic modi-
fications and analyzed their respective expression patterns
generated by Genevestigator.
First, using the Anatomy profiles (Gene Atlas tool), four
genes which have a well-documented retina specific
expression (CRX [Mm. 8008] [20], Rho [Mm.2965], PDE6
[Mm.39200] [21], and Nrl [Mm.20422] [22]), in fact
showed a strong expression in the retina (and its parent
categories), but no or only weak signals in other organs
(Fig. 1A). Furthermore, the spatial expression of both
Titin [Mm.26579], known to play a critical role for both
heart [23] and muscle [24] and BOP (Smyd1
[Mm.234274]), a heart and muscle specific transcription
factor [25] was restricted to the corresponding tissues (Fig.
1A) [see Additional file 1].
Second, to verify the reliability of the Development pro-
files (Gene Chronologer tool), we looked for genes anno-
tated as being developmentally regulated. Only a handful
of early embryonic genes have been described to date.
Among those we tested the RING finger protein gene
Rnf33 [Mm.28010] and Hoxal [Mm.197] a homeobox
transcription factor that regulates embryonic patterning
and organogenesis. Transcription of Rnf33 has been
shown to occur already in the mouse oocyte but not
beyond the eight-cell stage nor in adult tissues [26]. Hoxal
expression starts at E7.5 and begins to retreat caudally by
day E8.5 [27]. Both genes were found to be expressed
solely in the corresponding embryonic developmental
stage groups (Fig. 1B1 and 1B2) [see Additional file 1]. In
contrast, the gene encoding hemopexin (hx, [Mm.3485]),
a plasma glycoprotein known to be only lowly expressed
in embryos and newborn mice [28] showed an adult stage
specific expression profile (Fig. 1B3) with the strongest
signal at the latest stage, which reflects the fact that hxBMC Bioinformatics 2006, 7:311 http://www.biomedcentral.com/1471-2105/7/311
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Validation of expression profiles Figure 1
Validation of expression profiles. The results shown were calculated from 2138 arrays of type MG-U74Av2 (12 K). Similar 
results can be obtained using arrays of type Mouse430 2.0 (40 K) for categories available in both array types. For each gene, the 
signal intensity value indicated in each category is the average signal intensity value (of the corresponding probe set) from all 
arrays within this category. Average signal intensity values are available throughout all shown categories for all probe sets rep-
resented on the 12 K array. A. Anatomy expression profiles of genes shown in the literature to be preferentially expressed in 
muscle and heart (Mm.234274) or in retina (Mm.2965, Mm.39200, Mm.8008, Mm.20422). B1-B3. Development expression pro-
files of three genes previously shown to be expressed in oocytes and up to the 8-cell stage (Mm.28010), between E7.5 and E8.5 
(Mm.197), and in adult mouse but low in embryo or newborn mice (Mm.3485). Developmental stages are defined as pre-natal 
(given in Theiler stages (TS); a: TS-1 to 2, b: TS-3 to 5, c: TS-6 to 9, d: TS-10 to 13, e: TS-14 to 18, f: TS-19 to 23, g: TS-24 to 
27) or post-natal (given in days after birth; h: 0–3, i: 4–15, j: 16–63, k: 64–255, l: > 256). C and D. Response of Sirt1 
(Mm.351459) to a set of stimuli (C) and to genetic modifications (D). Only treatments or mutations inducing strong up or 
down regulation are shown. Effects described in the text are highlighted. These precompiled responses are log-ratios from the 
average signal intensity values of treatment versus control samples from a variety of experiments and tissues.
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gene expression reaches adult level not until the first year
of age [28].
Third, to test the Genevestigator output in terms of
responses to different stimuli (Response Viewer) and to
genetic modifications (Mutant Surveyor), we used Sirt1
[Mm.351459], a nuclear deacetylase that is closely associ-
ated with the longevity elicited by caloric restriction (CR,
[29], Fig. 1C) [see Additional file 1]. In mammals a char-
acteristic set of physiological changes takes place during
CR. Among those changes is the use of dietary fat or fat
mobilized from white adipose tissue for energy, and a
large reduction in blood insulin levels accompanied by an
increase in insulin sensitivity. It was shown that the flux of
metabolites under fasting conditions leads to an increase
in Sirt1 mRNA levels and that Sirt1 also controls glucose
metabolism through the regulation of PPAR co-activator 1
[30]. The Response Viewer correctly showed an up regula-
tion of Sirt1 in fasted mice, in mice which were put on a
fat diet, as well as in response to several insulin treat-
ments. No change or even a slight down regulation in
Sirt1 expression was observed in caloric restriction treat-
ments performed with Ames mice. This is consistent with
the fact that the pathways responsible for extending
lifespan in the dwarfs and in CR animals are not identical
[31]. In addition, we found Sirt1 severely up regulated in
response to dexamethasone, in accordance with the
reported increase of Sirt1 protein levels upon dexametha-
sone treatment measured by western blot analysis of 3T3-
L1 fibroblasts [32]. The Mutant Surveyor analysis revealed
a substantial increase of Sirt1 mRNA levels in mice with a
truncated growth hormone receptor (mutant 391), which
are characterized by marked male obesity associated with
hyperglycemia; in BDC2.5/NOD mice, which develop a
mild cellular infiltrate in the pancreatic islets of Langer-
han's (insulitis); and in C57BL/6J-ob/ob mice, which
exhibit a diabetes-like syndrome of hyperglycemia, glu-
cose intolerance and elevated plasma insulin levels [33]
(Fig. 1D). Hence, the Sirt1 expression profile in these
mouse strains reflects its role in controlling glucose
metabolism. Moreover, Sirt1 was found to be up regulated
in PPAR over-expressing mice, which is consistent with
the model that Sirt1 functions as a represser of genes that
drive white adipocyte differentiation and fat storage [32].
Remarkably, among the genetically modified strains that
showed increased Sirt1 expression were also telomerase-
deficient mice (Terc-/-, [34]), mice defective in the Ku86
DNA repair protein (Ku86-/-, [35]) and mice double defi-
cient for telomerase and Ku86 (Terc-/-/Ku86-/-, [36]) all
characterized by a premature-aging phenotype. This in
turn is consistent with the observation that the yeast Sirt1
ortholog Sir2, a central player in yeast aging, represses
transcription near telomeres [37] and that both Sir2 and
Ku86 are involved in non-homologous end joining,
which is used to repair breaks in DNA by ligation of the
free ends [38].
This validation approach clearly shows that Genevestiga-
tor is capable to detect biologically relevant trends in the
expression profiles of individual genes by combining
numerous normalized expression data sets using the same
technical platform, i.e. the Affymetrix system.
We further performed a second approach to test whether
Genevestigator can identify genes with known expression
profiles. Using the anatomy genome-centric querying
options, we created a list of the top 30 genes preferentially
expressed in the heart (Figure 2) [see Additional file 1]. Of
these, 12 could be spatially associated with the heart
based on the annotation "cardiac". Further the list com-
prises the NK2 transcription factor related locus 5 (Nkx2-
5, [Mm.26579]), a homeobox-containing gene specifi-
cally expressed in the developing heart [39]; the gene
encoding corin [Mm.332425], a multiple-domain type II
transmembrane serine protease highly expressed in the
heart with a binding site for NKX2.5 transcription factors
[40]; the cardiac troponin I (Tnni3, [Mm.358642]), a sar-
comeric protein gene exclusively expressed in the cardiac
muscle [41]; and FHL2 [Mm.6799], a LIM domain protein
preferentially expressed in the heart [42]. The remaining
genes are not yet associated with the heart or unknown,
evincing the potential of Genevestigator to identify novel
genes related to particular organs.
Based on our validation study, we conclude that with the
current set of data, Genevestigator generates high quality
results. Moreover, we expect that this quality will continue
to rise as the size of the dataset increases.
Conclusion
Using standardized protocols and systematic annotation,
biologically relevant trends in gene expression can be
identified. The combined average of several measure-
ments within an annotation category increases the confi-
dence about signal values obtained from these categories.
At the same time, the quality and power of the tools will
increase as more numerous and more diverse data
become available and are included. Unfortunately, several
interesting published experiments could not be included
owing to lacking experiment annotation, highlighting the
importance of proper and sufficient annotation with con-
trolled vocabularies and following detailed guidelines.
Furthermore, the availability of raw data (CEL files) gen-
erated with the 40 K array were sparsely available in repos-
itories. We therefore encourage authors to provide also
raw data when submitting their experiments to public
repositories.BMC Bioinformatics 2006, 7:311 http://www.biomedcentral.com/1471-2105/7/311
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Due to the compilation of data from different labs, marker
identification methods may be sensitive to arrays with sig-
nals resulting from very weak hybridization or signals that
are in the saturation range. For this reason, applying strict
quality-control measures based on raw data analysis is
imperative for robust analysis. Genevestigator can be used
either as a validation tool for genes already under study,
as a tool to create new hypotheses, or to identify marker
genes. Our results demonstrate that Genevestigator effec-
tively identifies biological mechanisms and meta-data
related marker genes.
Availability and requirements
Project name: Genevestigator; Project homepage: https://
www.genevestigator.ethz.ch; Operating system: platform
independent; Programming language: PHP4/MySQL;
Licence: free access to current tools for academics; Any
restrictions to use by non-academics: licence needed.
Identification of marker genes Figure 2
Identification of marker genes. Hierarchical cluster of the top 30 genes preferentially or specifically expressed in the heart. 
Results were calculated from 2138 arrays of type MG-U74Av2 (12 K).
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Probeset Annotation
 97777_at Mm.41974 [NK2 transcription factor related, locus 5 (Drosophila)]
 100593_at Mm.247470 [troponin T2, cardiac]
 102048_at Mm.10279 [ankyrin repeat domain 1 (cardiac muscle)]
 100403_at Mm.46514 [myosin, light polypeptide 7, regulatory]
 160582_at Mm.10728 [myosin binding protein C, cardiac]
 100921_at Mm.358642 [troponin I, cardiac]
 101071_at Mm.290003 [myosin, heavy polypeptide 6, cardiac muscle, alpha]
 101593_at Mm.133825 [cysteine rich protein 2]
 97319_at Mm.29467 [Ras-related associated with diabetes]
 100986_at Mm.6799 [four and a half LIM domains 2]
 103289_at Mm.332425 [corin]
 95693_at Mm.246432 [isocitrate dehydrogenase 2 (NADP+), mitochondrial]
 99009_at Mm.195803 [nicotinamide nucleotide transhydrogenase]
  99570_s_at Mm.227583 [ATPase, Ca++ transporting, cardiac muscle, slow twitch 2]
 102653_at Mm.239871 [ryanodine receptor 2, cardiac]
 104338_r_at Mm.2252 [plakophilin 2]
 99524_at Mm.311962 [solute carrier family 8 (sodium/calcium exchanger), member 1]
 103888_at Mm.323997 [RNA binding protein gene with multiple splicing]
  97172_s_at Mm.35670 [ATP-binding cassette, sub-family C (CFTR/MRP), member 9]
 100614_at Mm.201606 [myoglobin]
 102749_at Mm.12907 [cytochrome c oxidase, subunit VIIa 1]
 94214_at Mm.22220 [fatty acid binding protein 3, muscle and heart]
 101028_i_at Mm.360115 [actin, alpha, cardiac]
 93050_at Mm.1529 [myosin, light polypeptide 2, regulatory, cardiac, slow]
 101063_at Mm.712 [troponin C, cardiac/slow skeletal]
 93514_at Mm.7353 [myosin, light polypeptide 3]
 98616_f_at Mm.207435 [myosin, heavy polypeptide 7, cardiac muscle, beta]
 103084_at Mm.17235 [cysteine and glycine-rich protein 3]
 161001_at --- [similar to LOC363091 protein]
 104184_at Mm.2740 [natriuretic peptide precursor type B]BMC Bioinformatics 2006, 7:311 http://www.biomedcentral.com/1471-2105/7/311
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